Huub Schellekens - Een gezonde wereld
D16 Training - Conference Besides having a public session focusing on a specific theme on each of the workshops (M7, M12, M20, M
De Affaire Buck - Andere Tijden
eLearning module: Improving confidence by explaining key terminology – Biosimilars: From concern to confidence
VUB | Infopunt Proefdieronderzoek
Huub Schellekens - HR Business Partner - Feenstra | LinkedIn
Huub Schellekens – Studium Generale Universiteit Utrecht
Huub Schellekens, Professor of pharmaceutical biotechnology at Utrecht University: "We need 20 billion doses for the entire world population"
About - Huub Schellekens - Discovery Medicine
Follicular Carcinoma of Thyroid with Bone Metastasis
SciELO - Saúde Pública - Hubs to spread technology and save lives Hubs to spread technology and save lives
Realising the Full Potential of Biosimilars: Interviews with Three Key Opinion Leaders - European Medical Journal
Immunogenicity and aggregation of therapeutic proteins - American ...
eLearning – Biosimilars: From concern to confidence
For complex biosimilars in EU: drop clinical comparability
Daan CROMMELIN | Professor Emeritus | Utrecht University, Utrecht | UU | Department of Pharmaceutical Sciences | Research profile
Huub Schellekens | European Association of Hospital Pharmacists
Zomerportret 1. Huub Schellekens: 'Iedereen moet weer gaan doen waar hij goed in is' | medischcontact
Zomerportret 1. Huub Schellekens: 'Iedereen moet weer gaan doen waar hij goed in is' | medischcontact
Huub Schellekens - HR Business Partner - Feenstra | LinkedIn
Reza NEJADNIK | Associate Professor | PhD | University of Iowa, IA | UI | College of Pharmacy | Research profile
Zomerportret 1. Huub Schellekens: 'Iedereen moet weer gaan doen waar hij goed in is' | medischcontact
Professor Schellekens maakt medicijnen zelf - Zembla - BNNVARA
Opgestapt CBG-lid Huub Schellekens uit forse kritiek op 'de perversies van het systeem' - HUMAN - VPRO
Huub Schellekens – Studium Generale Universiteit Utrecht
A new way to manufacture small batches of biopharmaceuticals on demand | MIT News | Massachusetts Institute of Technology
